Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.
Cymbalta is a drug approved to treat fibromyalgia pain, as well as several psychiatric disorders including depression and anxiety disorders.
However, a Cymbalta withdrawal class action lawsuit has been filed over allegations that Eli Lilly and other companies involved with manufacturing, marketing, and distribution, alleging they failed to warn patients of potential Cymbalta side effects.
Allegations have surfaced that patients who stop taking Cymbalta experience Cymbalta side effects that are both more severe and more common than the drug’s makers indicated, also called “Cymbalta withdrawal” or “Cymbalta discontinuation syndrome.”
“Cymbalta withdrawal” would describe a situation with cravings for the drug and drug-seeking behavior, which has not been reported. Withdrawal is typically seen with drugs like opiates and other narcotics.
With Cymbalta discontinuation syndrome, patients allegedly experience serious Cymbalta side effects, but do not crave the drug or exhibit drug-seeking behaviors the way a stereotypical drug addict would.
Allegedly, a large number of Cymbalta patients have experienced this Cymbalta discontinuation syndrome. The Cymbalta side effects reportedly associated with Cymbalta discontinuation syndrome include “brain zaps,” painful flashes of light and the sensation that their brains have been electrocuted.
Additionally, patients have reported flu-like symptoms and muscle tremors/shakiness after ceasing treatment with Cymbalta. Some reports even include suicidal behavior and actions. These alleged symptoms may persist for weeks or even months.
The Cymbalta class action lawsuit further alleges that not only can Cymbalta cause Cymbalta discontinuation syndrome, but that the drug’s makers like Eli Lily were aware of the risk of this side effect and downplayed it in their application for the drug to the U.S. Food and Drug Administration (FDA) and the information released to the general public.
Allegedly, as many as half of the test subjects in clinical trials for Cymbalta experienced Cymbalta discontinuation syndrome symptoms. Additionally, it has been alleged that five test subjects killed themselves during the clinical tests for Cymbalta.
Allegations do not end there. The Cymbalta lawsuits have further alleged that Eli Lily continued to downplay the risk of Cymbalta discontinuation syndrome through a poorly-managed call center, which was responsible for handling reports of Cymbalta side effects like Cymbalta discontinuation syndrome.
The Cymbalta Class Action Lawsuit is Case No. 9366, in the U.S. District Court for the Central District of California.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Cymbalta attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Cymbalta class action lawsuit is best for you. [In general, Cymbalta withdrawal lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply.
ATTORNEY ADVERTISING
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2024 Top Class Actions® LLC
Various Trademarks held by their respective owners
This website is not intended for viewing or usage by European Union citizens.
Get Help – It’s Free
Join a Free Cymbalta Withdrawal Class Action Lawsuit Investigation
If you attempted to stop taking Cymbalta and suffered withdrawal symptoms, you may have a legal claim. See if you qualify by filling out the short form below.
An attorney will contact you if you qualify to discuss the details of your potential case at no charge to you.
Oops! We could not locate your form.